NuevaBio

The firm is led by founders Mani Subramanian, Manoj Desai, and Gans Ganapati. Their joint decision-making structure has not been publicly detailed, though the partnership model implies a shared investment committee approach typical of seed-stage biotech funds.

NuevaBio focuses on seed and early-stage investments, typically writing first checks for companies in pre-clinical or early clinical development. The firm does not publicly articulate a strategy for later-stage growth equity or public-market positions.

The firm's investment vehicle structure is not disclosed. Based on its early-stage focus and small team profile, NuevaBio is expected to make direct equity investments into portfolio companies rather than acting as a fund-of-funds allocator.

NuevaBio invests in biotechnology and life sciences broadly, encompassing therapeutics, diagnostics, and medical devices. The firm has not published a list of excluded sub-sectors, though its seed-stage orientation naturally precludes service-based healthcare or late-stage commercial assets.

The firm's sourcing model is not publicly detailed. Given its Palo Alto location and founder backgrounds, deal flow likely originates from academic institutions, research hospitals, and incubators within the Bay Area biotech cluster, supplemented by the founders' individual scientific networks.

NuevaBio does not publicly disclose assets under management, fund sizes, or capital deployment figures. Its operating model appears to rely on private, limited-partner capital raised through traditional closed-end venture structures, though this is an inference from its stage focus and team size.

NuevaBio is structured as a private equity firm, not a single family office. The firm is led by three founders and operates a venture capital model raising commitments from external limited partners.